BREAKING
NVIDIA (NVDA) eyes China AI chip re-entry as export licensing shifts to case-by-case review 3 days ago Qualcomm (QCOM) authorizes $20B stock repurchase program, raises quarterly dividend to $0.92 3 days ago UP Fintech Holding Limited Reports Strong 2025 Results 3 days ago FedEx (FDX) Q3 Earnings Crush Estimates: EPS of $5.25 Beats by 27% on $24B Revenue 3 days ago Cato Corporation 2025 Financial Results Summary 3 days ago GROY Posts Breakeven Q4 Earnings, Beating Estimates by 100% as Revenue Grows 34.2% YoY to $4.5M 3 days ago York Space Systems (YSS) Posts -$0.24 EPS vs. -$0.18 Est., Revenue Soars to $105.3M 3 days ago Scholastic (SCHL) Q3 Loss Narrows to $0.15/Share vs $0.36 Estimate, Revenue Misses at $329.1M 3 days ago Curis (CRIS) EPS Soars 210.8% to $1.23, But Revenue Plunges 67.1% to $1.1M 3 days ago Eton Pharmaceuticals (ETON) Q4 Revenue Surges 82.9% YoY to $21.3M, EPS Climbs 266.7% 3 days ago NVIDIA (NVDA) eyes China AI chip re-entry as export licensing shifts to case-by-case review 3 days ago Qualcomm (QCOM) authorizes $20B stock repurchase program, raises quarterly dividend to $0.92 3 days ago UP Fintech Holding Limited Reports Strong 2025 Results 3 days ago FedEx (FDX) Q3 Earnings Crush Estimates: EPS of $5.25 Beats by 27% on $24B Revenue 3 days ago Cato Corporation 2025 Financial Results Summary 3 days ago GROY Posts Breakeven Q4 Earnings, Beating Estimates by 100% as Revenue Grows 34.2% YoY to $4.5M 3 days ago York Space Systems (YSS) Posts -$0.24 EPS vs. -$0.18 Est., Revenue Soars to $105.3M 3 days ago Scholastic (SCHL) Q3 Loss Narrows to $0.15/Share vs $0.36 Estimate, Revenue Misses at $329.1M 3 days ago Curis (CRIS) EPS Soars 210.8% to $1.23, But Revenue Plunges 67.1% to $1.1M 3 days ago Eton Pharmaceuticals (ETON) Q4 Revenue Surges 82.9% YoY to $21.3M, EPS Climbs 266.7% 3 days ago
ADVERTISEMENT
Market News

Walgreens Boots Alliance posts Q2 earnings, cuts 2019 outlook

Retailing giant Walgreens Boots Alliance (WBA) posted its second-quarter 2019 earnings before the bell on Tuesday, April 2. For the quarter, sales inched 4.6% higher to $34.5 billion, while operating income slumped 23.3% to $1.5 billion. Earnings fell 8.3% year-over-year to $1.24 per diluted share, while adjusted EPS slipped 5.4% to $1.64 in the same period. […]

April 2, 2019 2 min read
Alphastreet Vertex Pharma Q4 2025 Earnings Results

Retailing giant Walgreens Boots Alliance (WBA) posted its second-quarter 2019 earnings before the bell on Tuesday, April 2. For the quarter, sales inched 4.6% higher to $34.5 billion, while operating income slumped 23.3% to $1.5 billion. Earnings fell 8.3% year-over-year to $1.24 per diluted share, while adjusted EPS slipped 5.4% to $1.64 in the same period. […]

Retailing giant Walgreens Boots Alliance (WBA) posted its second-quarter 2019 earnings before the bell on Tuesday, April 2.

For the quarter, sales inched 4.6% higher to $34.5 billion, while operating income slumped 23.3% to $1.5 billion.

Earnings fell 8.3% year-over-year to $1.24 per diluted share, while adjusted EPS slipped 5.4% to $1.64 in the same period.

For fiscal 2019, Walgreens now sees adjusted EPS growth to be roughly flat at constant currency rates, way lower than previous guidance of 7-12% percent growth.

Walgreens Boots Alliance (WBA) Q2 2019 Earnings Infographic
Walgreens Boots Alliance Q2 2019 Earnings Infographic

“The market challenges and macro trends we have been discussing for some time accelerated, resulting in the most difficult quarter we have had since the formation of Walgreens Boots Alliance,” stressed CEO Stefano Pessina.

“During the quarter, we saw significant reimbursement pressure, compounded by lower generic deflation, as well as continued consumer market challenges in the U.S. and UK. While we had begun initiatives to address these trends, our response was not rapid enough given market conditions, resulting in a disappointing quarter that did not meet our expectations. As a result, we are now expecting roughly flat adjusted EPS growth for fiscal 2019,” he added.

Net cash provided by operating activities in the second quarter was $735 million, while free cash flow amounted to $411 million.

Sales rose 7.3% at its Retail Pharmacy USA segment to hit $26.3 billion in the second quarter — excluding the benefit from acquired Rite Aid stores, organic sales growth was merely 1.6% year-over-year.

Earnings Calendar: Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

ADVERTISEMENT